New strategies for MGUS and smoldering multiple myeloma.
Kyle
Robert A
RA
Mayo Clinic Medical School, USA.
D004164:Diphosphonates / Q000627:therapeutic use; D019468:Disease Management; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D007145:Immunoglobulin kappa-Chains / Q000097:blood; D007146:Immunoglobulin lambda-Chains / Q000097:blood; D009101:Multiple Myeloma / Q000188:drug therapy / Q000517:prevention & control*; D009194:Myeloma Proteins / Q000032:analysis; D010265:Paraproteinemias / Q000188:drug therapy*; D010266:Paraproteins / Q000032:analysis; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013792:Thalidomide / Q000627:therapeutic use
D004164:Diphosphonates; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D009194:Myeloma Proteins; D010266:Paraproteins; D013792:Thalidomide